An Industry Commentary on Regulatory Issues – Microbiology | PDA Journal of Pharmaceutical
Science and Technology Skip to main content Main menu Home Content Current Issue Past …

Pharmaceutical and biotechnology companies are finding it increasingly difficult to produce
antibacterials that will be approved by regulatory agencies and be profitable once they …

The pharmaceutical industry plays an active role in policy surrounding the research,
discovery and development of new medicines. Along with this commitment, the …

Industry and other special advocacy groups have been vocal about the need for regulatory
reform to provide incentives for the industry to continue to develop antimicrobial compounds …

More than at any other moment in our history, it is imperative that we maintain fidelity to
sound science and ensure the correct use of the associated scientific vocabulary. This is …

Regulatory affairs (RA) play crucial roles in the pharmaceutical industry because they are
concerned with the lifecycle of healthcare products, they offer strategic, tactical, and …

Due to the emergence of antimicrobial resistance, it is essential that we have access to a
number of antibiotics to treat microbial infections. If we were to rely on just a few drugs, the …

The historic decline of technology stocks over the past three years has seen the
biopharmaceutical sector ravaged more than most. Investors are realising that there are too …

The antibacterial therapeutic area has been described as the perfect storm. Resistance is
increasing to the point that our hospitals encounter patients infected with untreatable …

There is a complex relationship between the pharmaceutical industry and society. The
industry, patients, physicians, regulators and politicians are all driven by their own agendas …